Ask AI
IDST for SCLC
Interactive Treatment Decision Tool for SCLC: Expert Guidance on Treatment

Released: November 26, 2025

Instructions

This Interactive Decision Support Tool provides personalized, guideline-based management recommendations for small-cell lung cancer (SCLC) based on the specific patient and disease characteristics you enter in the tool. Recommendations reflect contemporary expert consensus across staging, systemic therapy, radiation therapy, and CNS management. For the most accurate results, it is recommended that you have all relevant clinical, imaging, and treatment information available before you begin.

You will be prompted to enter key details about your patient, including disease stage (limited-stage or extensive-stage), performance status, comorbidities, organ function, presence of brain or other metastatic sites, prior therapies, timing of relapse, and other factors that influence treatment selection such as age/frailty, radiation eligibility, and contraindications to immunotherapy.

Click on your selections to advance through the tool. Your choices may be edited at any time by selecting the [change] icon next to the question you wish to modify and entering a new selection.

You can also access additional information throughout the tool by clicking the [i] information icon next to select items.

Once all required patient characteristics are entered, you will be asked to select the management approach you are currently considering. After confirming this choice, click Submit Patient Case to view individualized recommendations.

After reviewing your case-specific guidance, you will be briefly asked how the recommendations influenced your clinical decision-making. You may then enter a new patient scenario at any time by selecting the Start New Case button.

When using the tool, you will also have the following options:

  • Print or download a Case Summary, which includes your patient’s entered characteristics, your selected management plan, and the tool’s recommendations.
  • View the Additional Considerations section, which provides educational content on important cross-cutting issues in SCLC management such as the role of prophylactic cranial irradiation (PCI), MRI surveillance intervals, hyperfractionated vs once-daily thoracic radiation, and evaluation and treatment of brain metastases.

Access to and use of this Interactive Decision Support Tool titled, “Interactive Treatment Decision Tool for SCLC: Expert Guidance on Treatment” is provided subject to the following terms and conditions. PLEASE READ THESE TERMS CAREFULLY.

This Interactive Decision Support Tool is designed to is a unique, dynamic online resource that provides clear expert guidance on management decisions for individual patients with small-cell lung cancer (SCLC). In total, 5 experts are presented with myriad possible patient and disease characteristics combinations and asked to provide their treatment selection for each scenario. 

The material published by Decera Clinical Education reflects the views of the reviewers or authors, not those of Decera Clinical Education or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the FDA. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.

Although the information contained in the “Interactive Treatment Decision Tool for SCLC: Expert Guidance on Treatment” Interactive Decision Support Tool has been produced and processed from sources believed to be reliable, no warranty, expressed or implied, is made regarding the accuracy, adequacy, completeness, legality, reliability, or usefulness of any information. This disclaimer applies to both the isolated and aggregate uses of the information. Decera Clinical Education provides this information on an as-is basis. This disclaimer applies to all material published by Decera Clinical Education including but not limited to medical information or opinions. All warranties of any kind, expressed or implied, including but not limited to the implied warranties of merchantability, fitness for a particular purpose, freedom from contamination by computer viruses, and noninfringement of proprietary rights are disclaimed.

Any trademarks are the property of respective companies.

© 2025 Decera Clinical Education. All rights reserved.

Program Content